CV Therapeutics (CVTX) Announces $185 Million Transaction with TPG-Axon Capital for Half of Royalty for Lexiscan(TM) (regadenoson) Injection
More News related to CVTX
- Spring Brings 'Green Shoots' For Stocks
- Notable Mergers and Acquisitions of the Day 3/16: BCS, CVTX, BAM
- Astellas Pharma Terminates $16/Sh Offer for CV Therapeutics (CVTX), Clearing Way For Gilead
- Top 10 News Items 3/9-3/13: Stock Stage 4-Day Win Streak; Bank CEOs Make Upbeat Comments (C, JPM, BAC); GE (GE) Gets Rating Cut
- Unusual 11 Mid-Day Movers 3/12: BRNC, CVTX, SEH, MW Higher; MTG, PDII, NP, STLD Lower
More News related to Corporate News
- Hydrogenics Resumes Trading Under NASDAQ Symbol "HYGS"
- Varian Medical (VAR) to Highlight its New Range of Detectors at Annual RSNA Meeting in Chicago
- Manulife (MFC) Confirms No Exposure to Dubai World
- Activision's (ATVI) Call of Duty Amasses $3 Billion in Global Sales
- Seiko Epson to Transfer Sales Function of Small and Medium-Sized TFT LCD Business to Sony (SNE)
CV Therapeutics, Inc. (Nasdaq: CVTX) announced that TPG-Axon Capital has agreed to pay CV Therapeutics up to $185 million in exchange for rights to 50 percent of CV Therapeutics' royalty on North American sales of Lexiscan(TM) (regadenoson) injection. CV Therapeutics received $175 million on closing of the transaction and could receive a potential future milestone payment of $10 million. [JT]
Related Categories
Corporate NewsHot List
Stocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
